: A randomized, placebo-controlled trial of the safety and efficacy of tecovirimat for the treatment of patients with monkeypox virus disease
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 75N91019D00024-P00001-759102000025-5
Grant search
Key facts
Disease
mpoxStart & end year
20202025Known Financial Commitments (USD)
$9,824,009Funder
National Institutes of Health (NIH)Principal Investigator
LORI DODDResearch Location
United States of AmericaLead Research Institution
LEIDOS BIOMEDICAL RESEARCH, INC.Research Priority Alignment
N/A
Research Category
Therapeutics research, development and implementation
Research Subcategory
Clinical trial (unspecified trial phase)
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Randomized Controlled Trial
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Mpox Research Priorities
Therapeutics research, development and implementation
Mpox Research Sub Priorities
Development of equitable, accessible, safe & effective therapeutics
Abstract
The funding supports a clinical trial to identify effective treatments for monkeypox virus disease. Monkeypox virus is a re-emerging pathogen that causes monkeypox virus disease, a disease of epidemic potential that causes significant morbidity and can result in death. Human monkeypox cases have been increasing in sub-Saharan Africa since 2000 and sporadic outbreaks outside of Africa have occurred, with cases in the US and the UK in 2021. The similarity between MPXV and the variola virus, coupled with concerns about the potential of the variola virus as a potential bioterrorism agent, have placed monkeypox treatments at the forefront of public health and scientific research agendas in many countries.